-
1.发明公开公开(公告)号：US20240360210A1
公开(公告)日：2024-10-31
申请号：US18034326
申请日：2021-10-29
申请人： NOVARTIS AG
CPC分类号： C07K16/244 , A61K45/06 , A61P17/00 , A61K2039/505
摘要： The present invention relates to the treatment and/or prevention of atopic dermatitis or a related condition. More specifically, the invention relates to the administration of an IL-18 antagonist, e.g., an anti-IL-18 antibody or a fragment thereof, to treat or prevent atopic dermatitis or a related condition in a subject in need thereof.
-
公开(公告)号：US20240350740A1
公开(公告)日：2024-10-24
申请号：US18760445
申请日：2024-07-01
申请人： NOVARTIS AG
发明人： Andrew BRYANT , Heinrich BUETTGEN , Wolfgang Papst , Marie Picci
CPC分类号： A61M5/31513 , A61M5/001 , A61M5/28 , A61M5/31505 , A61P27/02 , A61F9/0017 , A61M2005/3104 , A61M5/3137 , A61M2005/3139 , A61M2005/31508 , Y10T29/49826
摘要： The invention provides a syringe for use in an ophthalmic injection. The syringe comprises a body, a stopper and a plunger. The body comprises an outlet at an outlet end and the stopper is arranged within the body such that a front surface of the stopper and the body define a variable volume chamber from which a fluid can be expelled though the outlet. The plunger comprises a plunger contact surface at a first end and a rod extends between the plunger contact surface and a rear portion. The plunger contact surface is arranged to contact the stopper but not couple thereto, such that the plunger can be used to force the stopper towards the outlet end of the body, reducing the volume of the variable volume chamber, but not to move the stopper away from the outlet end.
-
3.发明公开公开(公告)号：US20240350680A1
公开(公告)日：2024-10-24
申请号：US18440783
申请日：2024-02-13
申请人： NOVARTIS AG
发明人： Matthias EDER , Klaus KOPKA , Martin SCHÄFER , Ulrike BAUDER-WÜST , Michael EISENHUT , Walter MIER , Martina BENESOVA
IPC分类号： A61K51/04 , C07B59/00 , C07D257/02 , C07D295/145
CPC分类号： A61K51/0482 , A61K51/0402 , A61K51/0497 , C07B59/002 , C07D257/02 , C07D295/145
摘要： The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
-
公开(公告)号：US20240350489A1
公开(公告)日：2024-10-24
申请号：US18685551
申请日：2022-09-01
申请人： NOVARTIS AG
发明人： Souvik BHATTACHARYA , Bruno BIETH , Bruno CENNI , Peter END , Gordon GRAHAM , Michael JUHNKE , Rajesh Singh KARAN , Allison Donna MANN , Etienne PIGEOLET , Karin RAPP , Kim-Hien SIN , Huixin YU , Ying ZHANG
IPC分类号： A61K31/505 , A61K9/20 , A61K9/48 , A61P25/28
CPC分类号： A61K31/505 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/4858 , A61K9/4866 , A61P25/28
摘要： The invention concerns method of treating multiple sclerosis (MS) by administering a therapeutically effective dose of LOU064 or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20240317721A1
公开(公告)日：2024-09-26
申请号：US18571588
申请日：2022-06-22
申请人： NOVARTIS AG
发明人： Claudio BOMIO-CONFAGLIA , Saskia Maria BRACHMANN , Simona COTESTA , Marc GERSPACHER , Catherine LEBLANC , Fabio LIMA , Edwige Liliane Jeanne LORTHIOIS , Rainer MACHAUER , Robert MAH , Sophie RACINE , Pascal RIGOLLIER , Stefan STUTZ , Andrea VAUPEL , Nicolas WARIN , Rainer WILCKEN , Frédéric ZECRI
IPC分类号： C07D403/14 , A61K31/416 , A61K31/4162 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/547 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/675 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , C07D495/10 , C07D498/04 , C07D498/08 , C07D498/10 , C07D513/08 , C07F9/6584
CPC分类号： C07D403/14 , A61K31/416 , A61K31/4162 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/4985 , A61K31/499 , A61K31/4995 , A61K31/501 , A61K31/5025 , A61K31/519 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K31/541 , A61K31/547 , A61K31/55 , A61K31/551 , A61K31/553 , A61K31/675 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/107 , C07D495/10 , C07D498/04 , C07D498/08 , C07D498/10 , C07D513/08 , C07F9/6584
摘要： The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.
-
公开(公告)号：US20240317705A1
公开(公告)日：2024-09-26
申请号：US18233121
申请日：2023-08-11
申请人： Novartis AG
发明人： Birgitte Langer Eriksen , Magnus Gustafsson , Charlotte Hougaard , Thomas Amos Jacobsen , Martin R. Jefson , Gregg F. Keaney , Jessica Klein , Janus Schreiber Larsen , John A. Lowe, III , John M. McCall , Dorte Strøbæk , Nadia Lybøl von Schoubye
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/10 , C07D498/08
CPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/10 , C07D498/08
摘要： Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
-
公开(公告)号：US20240299574A1
公开(公告)日：2024-09-12
申请号：US18672871
申请日：2024-05-23
申请人： Novartis AG
IPC分类号： A61K47/68 , A61K31/4745 , A61K45/06 , A61P35/00 , C07K16/18
CPC分类号： A61K47/6803 , A61K31/4745 , A61P35/00 , C07K16/18 , A61K45/06
摘要： This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
公开(公告)号：US12084424B2
公开(公告)日：2024-09-10
申请号：US18319630
申请日：2023-05-18
申请人： NOVARTIS AG
发明人： Luigi Franchi , Shomir Ghosh , Gary Glick , Jason Katz , Anthony William Opipari, Jr. , William Roush , Hans Martin Seidel , Dong-Ming Shen , Shankar Venkatraman , David Guenther Winkler
IPC分类号： C07D277/36 , C07C307/06 , C07D215/36 , C07D231/18 , C07D239/26 , C07D263/46 , C07D307/64 , C07D307/79 , C07D317/62 , C07D333/34 , C07D487/04 , C07C335/42 , C07D213/71 , C07D231/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04
CPC分类号： C07D277/36 , C07C307/06 , C07D215/36 , C07D231/18 , C07D239/26 , C07D263/46 , C07D307/64 , C07D307/79 , C07D317/62 , C07D333/34 , C07D487/04 , C07C335/42 , C07D213/71 , C07D231/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/04
摘要： In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:
or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.-
公开(公告)号：US20240279267A1
公开(公告)日：2024-08-22
申请号：US17058562
申请日：2019-05-30
申请人： Novartis AG
发明人： Arthur Suckow , Fabio Tucci
IPC分类号： C07H21/00 , A61K31/713 , A61K47/54
CPC分类号： C07H21/00 , A61K31/713 , A61K47/543
摘要： Disclosed herein, inter alia, are lipid-modified nucleic acid compounds, their preparation, and their use.
-
公开(公告)号：US20240270738A1
公开(公告)日：2024-08-15
申请号：US18602126
申请日：2024-03-12
申请人： NOVARTIS AG
发明人： Christopher ADAIR , Katsumasa Nakajima , Rukundo Ntaganda , Julien Papillon , Troy Douglas Smith
IPC分类号： C07D417/12 , A61K45/06
CPC分类号： C07D417/12 , A61K45/06
摘要： A method of preparing compound of Formula (1), or a pharmaceutically acceptable salt thereof,
wherein R1 through R6 are as defined herein.
-
-
-
-
-
-
-
-
-
搜索结果
6128 条记录 (耗时 0.05 秒)
